ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1584

Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort

Milena Mimica1, Oslando Padilla 2, Felipe Aguilera 3, Fernando Cavalcanti 4, Eduardo Borba 5, Marlene Guibert-Toledano 6, Rosa Chacon-Diaz 7, Gloria Vasquez 8, Guillermo Pons-Estel 9, Mario Cardiel 10, Oscar Neira 11, Mary-Carmen Amigo 12, Eloisa Bonfa 13, Graciela Alarcón 14, Bernardo A. Pons-Estel 15 and Loreto Massardo 16, 1Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia. Universidad San Sebastián, Santiago, Chile., Santiago, Region Metropolitana, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Region Metropolitana, Chile, 3Universidad San Sebastián, Santiago, Region Metropolitana, Chile, 4Hospital das Clínicas da Universidade Federal de Pernambuco, Recife, Brazil, 5Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 6Servicio Nacional de Reumatología, Centro de Investigaciones Médico Quirúrgicas (CIMEQ), La Habana, Cuba, 7Servicio de Reumatología, Policlínica Méndez Gimón, Caracas, Venezuela., Caracas, Venezuela, 8University of Antioquia, Medellin, Antioquia, Colombia, 9Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 10Centro de Investigación Clínica de Morelia, SC, Morelia, México., Morelia, Mexico, 11Sección Reumatología, Hospital del Salvador. Universidad de Chile. Unidad de Reumatología. Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo., Santiago, Chile, Santiago, Chile, 12Servicio de Reumatología, Centro Médico ABC, Ciudad de México, México., Mexico, Mexico, 13Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, 14University of Alabama at Birmingham, Birmingham, 15Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina, 16Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia. Universidad San Sebastián, Santiago, Chile., Santiago, Chile

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at risk of accumulating damage, having an impaired quality of life and experiencing a premature death. The different domains and items of the SLICC/ACR Damage Index (SDI) and the predictors of their development and progression in patients from a large multiethnic, multinational Latin American Lupus Cohort were studied.

Methods: 1,385 SLE patients, with a recent SLE diagnosis (< 24 months and >6 months to comply with SDI definition), were studied and followed-up for a mean of 47.0 (SD 25.1) months. Socio-demographic and clinical variables were assessed. The 41 items and 12 domains of SDI were evaluated annually. Kaplan-Meier (Log-rank test) and Cox frailty models as multivariate analysis were performed.

Results: At cohort entry 565 patients (40.8%) had damage score ≥1, with a mean baseline SDI 0.66 (SD 1.01). During follow-up 658 patients (47.5%) accrued new damage ≥1, with a meantime between cohort entry and new damage of 33.2 months (SD 26.2). 11.3% accrued severe new damage (SDI ≥3 points).At last follow-up: 952 patients (68.7%) had a total damage score ≥1, with a mean final SDI of 1.57 (SD 1.67). 76 patients (5.5%) died during follow-up, at a mean time of 50.0 (SD 23.5) months from cohort entry; 56.6% of they had damage at baseline, with a mean SDI of 1,12 (SD 1.4).   The highest proportion of new damage occurrence was in the skin domain, followed by renal and neuropsychiatric domains, and the lowest proportion were for gonadal and malignancy domains, as shown in Figure 1 of damage accrual for the 12 SDI domains.   Multivariate analysis (including gender, age, medical coverture, country of origin, race, rural or urban residency, socioeconomic status, education years, SLE duration, and diagnosis delay), to investigate predictors of different damage domains, showed that higher baseline SLEDAI scores associated with a significant Hazard Risk for new damage in the neuropsychiatric, ocular, cardiovascular, skin, pulmonary and renal domains. There were differences according to country of origin, with more new damage occurring in patients from Perú and Argentina, and with less damage accrual occurring in those from Guatemala, Cuba and Brazil. No other differences were observed.   At last follow-up: alopecia was the most frequent SDI item (30.4% SLE) followed by proteinuria  >3.5g/d (11.2%), estimated glomerular filtration range < 50% (9.0%), and seizures requiring therapy for >6 months (7.5%). The other 37 SDI items were present in < 5% of the members of the cohort.

Conclusion: In this cohort, skin (mostly alopecia) was the most prevalent domain in damage accrual. SLEDAI predicts damage accrual in several domains, including major organs, reinforcing the need for early treatment intervention to minimize the inflammatory process and consequent damage. Relevant differences according to country of origin were identified.

Figure 1: Accumulative damage curves in the 12 domains of the SDI during follow-up


Disclosure: M. Mimica, None; O. Padilla, None; F. Aguilera, None; F. Cavalcanti, None; E. Borba, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4), 2, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #306879/2018-2), 2; M. Guibert-Toledano, None; R. Chacon-Diaz, None; G. Vasquez, None; G. Pons-Estel, None; M. Cardiel, None; O. Neira, None; M. Amigo, None; E. Bonfa, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #305068/2014-8), 2, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4 and #2010/10749-0), 2; G. Alarcón, None; B. Pons-Estel, None; L. Massardo, None.

To cite this abstract in AMA style:

Mimica M, Padilla O, Aguilera F, Cavalcanti F, Borba E, Guibert-Toledano M, Chacon-Diaz R, Vasquez G, Pons-Estel G, Cardiel M, Neira O, Amigo M, Bonfa E, Alarcón G, Pons-Estel B, Massardo L. Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-accrual-of-damage-over-time-in-patients-with-sle-results-from-a-multinational-latin-american-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-accrual-of-damage-over-time-in-patients-with-sle-results-from-a-multinational-latin-american-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology